Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study
| dc.contributor.author | Trukhin, D. | |
| dc.contributor.author | Grohe, C. | |
| dc.contributor.author | Paz-Ares, L. G. | |
| dc.contributor.author | Dvorkin, M. | |
| dc.contributor.author | Chen, Y. | |
| dc.contributor.author | Hotta, K. | |
| dc.contributor.author | Statsenko, G. | |
| dc.contributor.author | Hochmair, M. J. | |
| dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
| dc.contributor.author | Ji, J. H. | |
| dc.contributor.author | Voitko, O. | |
| dc.contributor.author | Poltoratskiy, A. | |
| dc.contributor.author | Verderame, F. | |
| dc.contributor.author | Havel, L. | |
| dc.contributor.author | Bondarenko, I. | |
| dc.contributor.author | Armstrong, J. | |
| dc.contributor.author | Byrne, N. | |
| dc.contributor.author | Jiang, H. | |
| dc.contributor.author | Goldman, J. W. | |
| dc.contributor.author | Reinmuth, N. | |
| dc.date.accessioned | 2021-03-02T16:34:16Z | |
| dc.date.available | 2021-03-02T16:34:16Z | |
| dc.identifier.citation | Grohe C., Paz-Ares L. G. , Dvorkin M., Chen Y., Hotta K., Trukhin D., Statsenko G., Hochmair M. J. , ÖZGÜROĞLU M., Ji J. H. , et al., "Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study", ONCOLOGY RESEARCH AND TREATMENT, cilt.43, ss.149, 2020 | |
| dc.identifier.issn | 2296-5270 | |
| dc.identifier.other | av_fbf915c2-0d98-45ca-aafd-7f6bcea89113 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/3200 | |
| dc.language.iso | eng | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Onkoloji | |
| dc.title | Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study | |
| dc.type | Makale | |
| dc.relation.journal | ONCOLOGY RESEARCH AND TREATMENT | |
| dc.contributor.department | Evangel Lungenklin Berlin Buch , , | |
| dc.identifier.volume | 43 | |
| dc.identifier.startpage | 149 | |
| dc.identifier.endpage | 149 | |
| dc.contributor.firstauthorID | 2287946 |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Makale [92797]